ProteoNic, a leading provider of premium vector technology and services for production of biologics, and FyoniBio, a contract development organization for biopharmaceuticals, have entered into a technology licensing agreement. Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic techno-logy in its proprietary CHOnamite platform. As a result, FyoniBio’s clients will profit from extended options for cell line development and significantly reduced cost of goods for their products.

ProteoNic, a leading provider of premium vector technology and services for production of biologics, and FyoniBio, a contract development organization for biopharmaceuticals, have entered into a technology licensing agreement. Under the agreement, FyoniBio gains worldwide, non-exclusive commercial rights for application of ProteoNic techno-logy in its proprietary CHOnamite platform. As a result, FyoniBio’s clients will profit from extended options for cell line development and significantly reduced cost of goods for their products.

ProteoNic’s premium protein expression technology 2G UNic improves production levels across a range of mammalian cell types, selection systems and product classes. This is achieved by the combined effect of novel genetic elements which together boost recombinant protein production on various levels. The technology increases production levels of complex proteins which are difficult to produce, including bi-specifics and fusion proteins as well as levels of products already in the multiple g/L range. Additionally, 2G UNic can be used to boost the performance of other expression enhancing technologies.